Atlas Trials

Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Clinical trial NCT06405061 · SUSPENDED

Trial details

NCT number
NCT06405061
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
SUSPENDED
Phase
Phase 2
Study type
INTERVENTIONAL
AdebrelimabHepatocellular Carcinoma
Start date
2024-05-01
Primary completion
2027-05-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.